Clinical Trials Browser

OTHER × ensartinib × 90 days × Clear all

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03420508 2026-02-05

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Phase 2 Active not recruiting

Melanoma

NCT07354061 2026-01-21

TD-ENSEMBLE

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung